Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
NCT06007781Phase 1Completed
- Sponsor
- HilleVax
- Start
- Aug 2023
- Primary completion
- May 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in norovirus gastroenteritis comparing HIL-214 with Placebo (2 arms). Primary endpoints: Safety of HIL-214 Compared to Placebo - AEs Leading to Trial Withdrawal, Safety of HIL-214 Compared to Placebo - Solicited Local Adverse Events and 1 more. Started Aug 2023; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT06007781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007781.